Roth Capital notes that the DOJ has officially rescheduled cannabis products that are FDA approved and products regulated by state medical programs to Schedule 3 and points out that an ALJ hearing has been scheduled on June 29 to assess broader rescheduling, including adult-use. Highlighting the language that “holders of state medical marijuana licenses will no longer be subject to the deduction disallowance imposed by Section 280E,” the firm believes the final order is “extremely favorable for” go-forward 280E; retrospective 280E; the potential for imports/exports; ultimate adult-use rescheduling; and “sector investability.” Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN) and Trulieve Cannabis (TCNNF).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Trump Trade: Trump officials reclassify state-licensed medical marijuana
- TLRY, CGC, CRON: Cannabis Stocks Sink despite Marijuana Reclassification
- Trump administration reclassifies state-licensed medical marijuana
- Trump administration expected to reclassify cannabis soon, Axios reports
- Aurora Cannabis Buys EU GMP Producer Safari Flower Company in $26.5 Million Deal